Controversies around epithelial–mesenchymal plasticity in cancer metastasis
ED Williams, D Gao, A Redfern… - Nature Reviews Cancer, 2019 - nature.com
Experimental evidence accumulated over decades has implicated epithelial–mesenchymal
plasticity (EMP), which collectively encompasses epithelial–mesenchymal transition and the …
plasticity (EMP), which collectively encompasses epithelial–mesenchymal transition and the …
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …
[HTML][HTML] New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities
Epithelial-to-mesenchymal transition (EMT) mechanism is responsible for metastasis and
migration of cancer cells to neighboring cells and tissues. Morphologically, epithelial cells …
migration of cancer cells to neighboring cells and tissues. Morphologically, epithelial cells …
Targeting EMT in cancer with repurposed metabolic inhibitors
Epithelial-to-mesenchymal transition (EMT) determines the most lethal features of cancer,
metastasis formation and chemoresistance, and therefore represents an attractive target in …
metastasis formation and chemoresistance, and therefore represents an attractive target in …
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
The success of next-generation androgen receptor (AR) pathway inhibitors, such as
abiraterone acetate and enzalutamide, in treating prostate cancer has been hampered by …
abiraterone acetate and enzalutamide, in treating prostate cancer has been hampered by …
Update on epithelial-mesenchymal plasticity in cancer progression
R Fontana, A Mestre-Farrera… - Annual Review of …, 2024 - annualreviews.org
Epithelial-mesenchymal transition (EMT) is a cellular process by which epithelial cells lose
their characteristics and acquire mesenchymal traits to promote cell movement. This …
their characteristics and acquire mesenchymal traits to promote cell movement. This …
A convergence-based framework for cancer drug resistance
DJ Konieczkowski, CM Johannessen, LA Garraway - Cancer cell, 2018 - cell.com
Despite advances in cancer biology and therapeutics, drug resistance remains problematic.
Resistance is often multifactorial, heterogeneous, and prone to undersampling …
Resistance is often multifactorial, heterogeneous, and prone to undersampling …
[HTML][HTML] Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways
X Lu, F Yang, D Chen, Q Zhao, D Chen… - … Journal of Biological …, 2020 - ncbi.nlm.nih.gov
Docetaxel is the first-line chemotherapy agent for metastatic prostate cancer. However, the
emergence of resistance diminishes its efficacy and limits the survival benefit. Quercetin is a …
emergence of resistance diminishes its efficacy and limits the survival benefit. Quercetin is a …
The role of CD44 in epithelial–mesenchymal transition and cancer development
CD44, a multi-structural and multifunctional transmembrane glycoprotein, was initially
identified as a receptor for hyaluronan that participates in both physiological and …
identified as a receptor for hyaluronan that participates in both physiological and …
Mechanisms of taxane resistance
SM Maloney, CA Hoover, LV Morejon-Lasso… - Cancers, 2020 - mdpi.com
Simple Summary Drug resistance is prevalent in many types of cancer and decreases
patient survival. The taxanes are anti-mitotic chemotherapeutic agents, widely used since …
patient survival. The taxanes are anti-mitotic chemotherapeutic agents, widely used since …